- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05108558
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Beginning approximately 3 years ago, the investigators' team sought to achieve further improvements with CCH through the addition of more aggressive modeling therapies. Results from a comparison of CCH alone vs CCH and traction with RestoreX demonstrated a mean 33.8 degree (49%) curvature improvement with combined therapy compared to 19-20 degrees (30-31%) with CCH alone or CCH and other traction devices). These results currently represent the greatest improvements with CCH in published literature and further build upon phase IIb results which demonstrated that mechanical traction (via manual modeling in the phase IIb trial) represents a critical factor in achieving improvements with CCH.
The investigators' team additionally published a survey of men who had experienced suspected penile fractures with CCH and demonstrated greater curvature improvements without any loss / worsening of erectile function. This critical study highlighted that conservative management of suspected fractures should not only be considered a standard of care in managing suspected fractures, but also that these men achieved better final outcomes (again highlighting the importance of the combination of mechanical curvature correction in addition to CCH management).
Based on the above findings, the investigators' team began performing a more aggressive manual modeling protocol. This novel protocol included several notable innovations: dilution of the 0.9 mg of CCH in 0.7 ml of diluent, injection to the erect penis to assure accurate injection, repeat curvature assessments with each series (due to changing of the point of maximal curvature), incorporation of RestoreX traction therapy post injection, and 'aggressive' manual modeling (equivalent of 10-15 lbs of force) to achieve curvature correction. Preliminary (unpublished - abstract submitted to SMSNA 2021) results from these men demonstrated a median ~60% curvature improvement. Importantly, several of the patients had previously undergone 8 CCH injections with outside providers and were able to similarly achieve a median 60% improvement with the investigators' injection / modeling protocol.
These preliminary findings have several important ramifications for the treatment of PD:
- Men who have previously not achieved adequate curvature correction with 4 series of CCH injections may benefit from additional injections using a more aggressive traction protocol.
- A more aggressive traction protocol would benefit patients to achieve greater outcomes than with previously reported protocols.
1.2 Investigational Treatments
The current study would randomize men 1:3 into one of two treatment cohorts: 1. Observation followed by CCH or 2. CCH followed by observation. This study design offers the benefits of a randomized, controlled trial (highest level of evidence). RCTs are particularly important in PD, where the disease changes over time in a percentage of men as a function of its natural history. This would also allow blinding of measurements using photographs (single-blinded assessments), which provides further study rigor.
- No treatment (control) followed by CCH. Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees). Interval assessments would be performed with the 1st injection of each series, and final assessments would then be performed 6 weeks following the final injection.
- CCH followed by no treatment. Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Interval assessments would be performed with the 1st injection of each series and 6 weeks following completion of treatment. Men then would not undergo any additional treatments for 6 months, after which final assessments would then performed.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Landon Trost, MD
- Phone Number: 801-655-0015
- Email: email@mfp.clinic
Study Locations
-
-
Utah
-
Orem, Utah, United States, 84057
- Recruiting
- The Male Fertility and Peyronie's Clinic
-
Contact:
- Landon Trost, MD
- Phone Number: 888-655-0015
- Email: trost.landon@mfp.clinic
-
Sub-Investigator:
- Benjamin D. Green, Economics/MA
-
Sub-Investigator:
- Holli Burgon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men with Peyronie's Disease
- >18 years old
- Curvature ≥30 degrees
- Previously completed 6-8 CCH injections
- Prior minimal (<20% and/or <10 degrees) responsiveness to CCH administration
- Prior CCH injections must have been performed without use of a Restorex traction device and used the IMPRESS protocol
- Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors
- The patient exhibits a palpable plaque consistent with Peyronie's Disease
Exclusion Criteria:
- Prior surgical treatment on the penis (other than circumcision)
- Any contraindications to CCH - as determined by the PI
- Inability to complete 8 additional CCH injections
- Severe plaque calcification (i.e. >1 cm shadowing)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control - Crossover to CCH
Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments.
Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees).
Final assessments would then be performed 6 weeks following the final injection.
|
Patients will be randomized 1:3 into the control arm.
After undergoing baseline assessments, control men will not undergo treatments for 6 months.
They will then have repeat assessments and receive up to 8 CCH injections.
They will then have final assessments performed 6 weeks after treatment.
Other Names:
Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
|
Experimental: Collagenase Clostridium Histolyticum
Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees).
Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.
|
Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
Patients will be randomized 3:1 into the CCH administration arm.
After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Penile Curvature
Time Frame: 6 months
|
Compare the change in degree of penile curvature from baseline (using a goniometer) between control and treatment groups at 6 months
|
6 months
|
Peyronie's Disease Questionnaire Outcomes
Time Frame: 6 months
|
Compare Peyronie's Disease Questionnaire outcomes between control and treatment groups at 6 months using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Index of Erectile Function Outcomes
Time Frame: 6 months
|
Compare International Index of Erectile Function Outcomes between control and treatment groups at 6 months
|
6 months
|
Penile Curvature Compared to Baseline
Time Frame: 12 months
|
Compare penile curvature changes (degrees) in control men at baseline and 12 months (i.e.
prior to and following cross-over to CCH) - using goniometer
|
12 months
|
Penile Length Compared to Baseline
Time Frame: 12 months
|
Compare penile length changes in control men at baseline and 12 months (i.e.
prior to and following cross-over to CCH)
|
12 months
|
Compare Peyronie's Disease Questionnaire to Baseline
Time Frame: 12 months
|
Compare PDQ changes in control men at baseline and 12 months (i.e.
prior to and following cross-over to CCH) using the Peyronie's Disease Questionnaire (15 items; subdomains - psychological and physical (Q1-6, 0-24), penile pain (Q7-9; 0-30), symptom bother (Q10-15; 0-16); 12 and 14 (Y/N q's); lower is better.
|
12 months
|
Compare International Index of Erectile Function to baseline
Time Frame: 12 months
|
Compare International Index of Erectile Function changes in control men at baseline and 12 months (i.e.
prior to and following cross-over to CCH)
|
12 months
|
Penile Length Between Groups
Time Frame: 6 months
|
Compare penile length changes between control and treatment groups at 6 months
|
6 months
|
Adverse events - 6 months - pain, sensation, swelling
Time Frame: 6 months
|
Report adverse events at the 6-month time point
|
6 months
|
Adverse events - 12 months - pain, sensation, swelling
Time Frame: 12 months
|
Report adverse events at the 12-month time point
|
12 months
|
Change in penile curvature durability
Time Frame: 6 months
|
Report changes in penile curvature degree between the 6 and 12-month assessments for CCH men by goniometer.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Landon Trost, MD, CURE PD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CUREPD 103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peyronie's Disease
-
Men's Health BostonCompleted
-
University Hospital, MontpellierCompletedPeyronie DiseaseFrance
-
Hopital FochDornier MedTech SystemsRecruitingPenile Diseases | Peyronie DiseaseFrance
-
King's College LondonCompletedPeyronie DiseaseUnited Kingdom
-
Odense University HospitalUnknown
-
Endo PharmaceuticalsCompletedPeyronie's DiseaseUnited States, Denmark, France, Germany, Italy, New Zealand, Spain, Sweden, United Kingdom
-
Endo PharmaceuticalsCompleted
-
University Hospital, ToulouseRecruitingPeyronie DiseaseFrance
-
University of Roma La SapienzaRecruitingPeyronie DiseaseItaly
Clinical Trials on Control - Crossover to CCH
-
Noema Pharma AGRecruitingTuberous Sclerosis ComplexUnited States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
-
University of Southern CaliforniaPatient-Centered Outcomes Research InstituteCompleted
-
University of Roma La SapienzaCompleted
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema of Upper Arm | Lymphedema, Breast CancerUnited States
-
VA Office of Research and DevelopmentRecruitingChronic Kidney Disease (CKD) Stage 5 | Kidney Dysfunction Requiring Dialysis (KDRD) | Dialysis DependencyUnited States
-
Agile TherapeuticsCompleted
-
University of BernSwiss National Science FoundationUnknownColorectal CancerSwitzerland
-
Gregory GilotThe Cleveland Clinic; LifeNet HealthActive, not recruiting
-
Sorlandet Hospital HFUnknown
-
Servicio Canario de SaludUniversity of La LagunaCompleted